MedTrace Logo

Reduction of Antibiotic Therapy by Biomakers in Patients With CAP Episodes (REDUCE Study)

NCT01964495 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 468

Last updated 2022-04-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate two different treatment strategies in patients admitted to hospital with Community Acquired Pneumonia. The investigators hypothesize treatment according to both procalcitonin (PCT) and C-reactive protein (CRP) will be effective in reducing the length of antibiotic treatment.

Conditions

  • Community Acquired Pneumonia

Interventions

DRUG

Discontinuation of treatment according to CRP levels

The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.

DRUG

Discontinuation of treatment according to PCT levels

The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.

DRUG

Treatment according to current guidelines

Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.

Sponsors & Collaborators

  • Foreest Medical School

    collaborator UNKNOWN

  • Pulmoscience

    collaborator UNKNOWN

  • Medical Center Alkmaar

    lead OTHER

Principal Investigators

  • Ruud Duijkers, MSc, MD · Medisch Centrum Alkmaar

  • Wim G Boersma, MD, PhD, MSc · Medisch Centrum Alkmaar

  • Dominic Snijders, MSc, PhD, MD · Slotervaart ziekenhuis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-05
Primary Completion
2017-01-20
Completion
2017-01-20

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01964495 on ClinicalTrials.gov